Dupilumab treatment improves signs, symptoms, quality of life and work productivity in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double blind, placebo-controlled trial - Supplementary material

Description

Supplementary methods Supplementary Table I. Instruments used to assess efficacy outcomes Supplementary Table II. Endpoints pre-specified in the testing hierarchy Supplementary Table III. Additional baseline disease characteristics Supplementary Table IV. Use of rescue medication during the treatment period Supplementary Fig 1. Study flow diagram Supplementary Figure 2. Patient disposition Supplementary Fig 3. (A) Percent change from baseline in HF-mTLSS over time through week 16. (B) Percent change from baseline in weekly average of daily HF-Peak Pruritus NRS over time through week 16. (C) Change from baseline in weekly average of daily HF-Peak Pain NRS over time through week 16. (D) Percent change from baseline in HECSI score over time through week 16. (E) Proportion of patients achieving HECSI-75 over time through week 16. (F) Change from baseline in percent surface area of hand and involvement with AD over time through week 16. (G) Change from baseline in QoLHEQ over time through week 16. (H) Change from baseline in weekly average of daily Sleep NRS over time through week 16 Supplementary Fig 4. Time to first rescue treatment use during the 16-week treatment period Supplementary Fig 5. Sensitivity analyses (A) Primary endpoint sensitivity analysis: proportion of patients with HF-IGA 0/1 at week 16 using all observed values and last observation-carried forward. (B) Key secondary endpoint sensitivity analysis: proportion of patients with ≥4-point reduction in weekly average of daily Peak Pruritus NRS at week 16 using all observed values and last observation-carried forward.

Categories

Funding

Licence